Sars-cov-2 y sus efectos en el primer trimestre en Argentina
DOI:
https://doi.org/10.22529/me.2021.6(1)05Palabras clave:
SARS-CoV-2, COVID-19, cuarentena, mortalidad, letalidad.Resumen
INTRODUCCIÓN: El nuevo virus SARS-CoV-2 es causante de una enfermedad llamada COVID-19 que puede tornarse grave e incluso mortal. El número de casos y fallecidos reportados y el impacto a nivel socioeconómico dan una idea de la gravedad a nivel global que ha generado el mismo. Al ser un nuevo virus, se desconoce aún varios aspectos de este, por lo que el objetivo de este artículo es resumir los principales descubrimientos en torno a este nuevo virus y analizar los efectos de este en Argentina durante el primer trimestre del año en curso, con énfasis en la tasa de infección, la tasa de mortalidad y los casos recuperados para evaluar si las medidas de aislamiento y protección han sido efectivas. DESARROLLO: Para esto se graficó el número de infectados, número de recuperados y número de fallecidos bajo diferentes enfoques, además de realizar una revisión de la literatura sobre su origen, mecanismo de infección, síntomas, métodos de diagnóstico, tratamiento, vacuna y medidas de atenuación. CONCLUSIÓN: Se concluye que aún quedan muchos vacíos que llenar sobre información de este virus para poder aplicar una solución farmacológica, mientras tanto la recomendación por parte de la Organización Mundial de la Salud y el Ministerio de Salud Argentino es mantener el distanciamiento social y el uso obligatorio de mascarillas.Descargas
Referencias
Huang, C., Wang, Y., Li, X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
Zhao, D., Yao, F., Wang, L., et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. J. Infect. Dis. 2020; 21. https://doi.org/10.1093/cid/ciaa247
Corman, V. M., Muth, D., Niemeyer, D., & Drosten, C. Hosts and Sources of Endemic Human Coronaviruses. Adv. Virus Res. 2018; Vol. 100, pp. 163-188. https://doi.org/10.1016/bs.aivir.2018.01.001
Jiang, F., Deng, L., Zhang, L., YinCai, Cheung, C. W., & Xia, Z. Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020 1-5. https://doi.org/10.1007/s11606-020-05762-w
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. The proximal origin of SARS-CoV-2. Nat. Med. 2020. https://doi.org/10.1038/s41591-020-0820-9
Walls, A. C., Park, Y. J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020. https://doi.org/10.1016/j.cell.2020.02.058
Wan, Y. Molecular mechanism for antibodydependent enhancement of coronavirus. J. Virol. 2020; 94(5):e02015-19. https://doi.org/10.1164/rccm.200702-271OC
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. Receptor Recognition by the Novel Coronavirus from Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. J. Virol. 2020; 94(7). https://doi.org/10.1128/JVI.00127-20
Wrapp, D., Wang, N., Corbett, K. S., et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483): 1260-1263. https://doi.org/10.1126/science.aax0902
Zhang, J., Ma, X., Yu, F., Liu, J., Zou, F., & Pan, T. Teicoplanin potently blocks the cell. BioRxiv. 2020; 1-7. (DOI: https://doi.org/10.1101/2020.02.05.935387.)
Zhang, C., Shi, L., & Wang, F.-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol. Hepatol. 2020; 1-3. https://doi.org/10.1016/S2468-1253(20)30057-1
Zhang, T., Wu, Q., & Zhang, Z. Pangolin homology associated with 2019-nCoV. BioRxiv. 2020; 950253. https://doi.org/10.1101/2020.02.19.950253
Zhang, T., Wu, Q., & Zhang, Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr. Biol. 2020. https://doi.org/10.1016/j.cub.2020.03.022
Lirong Zou. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N. Engl. J. Med. 2020; 1-3. https://doi.org/10.1056/NEJMc2001737
Fauci, A., Lane, C., & Redfield, R. R. Covid19 - Navigating the Uncharted. N. Engl. J. Med. 2020;1-2. https://doi.org/10.1056/NEJMe2002387
Holshue, M., DeBolt, C., Lindquist, S., et al. First Case of 2019 Novel Coronavirus in the United States. N. Engl. J. Med. 2020; 1-9. https://doi.org/10.1056/NEJMoa2001191
Lauer, S.-A., Grantz, K.-H., Bi, Q., et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Intern. Med. 2020. https://doi.org/10.7326/M20-0504
Koh, G. C.-H., & Hoenig, H. How Should the Rehabilitation Community Prepare for 2019nCoV? Arch Phys Med Rehabil. 2020. https://doi.org/10.1016/j.apmr.2020.03.003
Wang J, Wang BJ, Yang JC, et al. Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures. Zhonghua Shao Shang Za Zhi. 2020. 10.3760/cma.j.cn50112020200307-00132.
Rismanbaf, A., & Zarei, S. Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy; a Letter to Editor. Acad Emerg Med. 2020; 8(1): e17. http://journals.sbmu.ac.ir/aaem.
Cheng, Y., Luo, R., Wang, K., Zhang, M., Wang, Z., & Dong, L. Kidney impairment is associated with in-hospital death of COVID19 patients. MedRxiv. 2020; 1-21. https://doi.org/10.1101/2020.02.18.20023242
Ungaro, R. C., Sullivan, T., Colombel, J.-F., & Patel, G. What Should Gastroenterologists and Patients Know About COVID-19? Clin. Gastroenterol. Hepatol. 2020; 1-12. https://doi.org/10.1016/j.cgh.2020.03.020
Touret, F., & de-Lamballerie, X. Of chloroquine and COVID-19. Antiviral Res. 2020; 177: 1-2. https://doi.org/10.1016/j.antiviral.2020.104762
Baron, Devaux, C., Colson, P., D., & Rolain, J.-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int. J. Antimicrob. Agents. 2020; 1-7. https://doi.org/10.1016/j.ijantimicag.2020.105944
Gautret, P., Lagier, J.-C., Parola, P., Hoang, V.-T., Meddeb, L., & Mailhe, M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int. J. Antimicrob. Agents. 2020. https://doi.org/10.1016/j.ijantimicag.2020.105949
Casadevall, A., & Pirofski, L.-a. The convalescent sera option for containing COVID-19. J Clin Invest. 2020. https://doi.org/10.1172/JCI138003
Luke, T., Casadevall, A., Watowich, S., Hoffman, S., Beigel, J., & Burgess, T. Hark back: passive immunotherapy for influenza and other serious infections. Crit Care Med. 2010; 38(4 suppl): e66-e73. https://doi.org/10.1097/CCM.0b013e3181d44c1e
Law, P. Emergent Serum Therapy and Antibody Medicine to Counteract Sudden Attacks of COVID-19 and Other Pathogenic Epidemics. Regen. Med. 2020; 9, 1-7. https://doi.org/10.4236/ojrm.2020.91001
Chen, W.-H., Strych, U., Hotez, P., & Bottazzi, M.-E. The SARS-CoV-2 Vaccine Pipeline: An Overview. Curr. Trop. Med. Rep. 2020; 1-4. https://doi.org/10.1007/s40475-020-00201-6
China CDC 2020. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19). China CDC Weekly. 2020; 2(8): 113-122. https://doi.org/10.46234/ccdcw2020.032
Yinon M. Bar-On, Avi Flamholz, Rob Phillips & Ron Milo. SARS-CoV-2 (COVID-19) by the numbers. Elife. 2020. Search in: https://elifesciences.org/articles/57309. https://doi.org/10.7554/eLife.57309.sa2
Riou, J., Counotte, M., Hauser, A., & Althaus, C. Adjusted age-specific case fatality ratio duringcovid-19 epidemic in Hubei, China, January and February 2020. MedRxiv. 2020; 1-10. https://doi.org/10.1101/2020.03.04.20031104
Li, Q., Guan, X., & Wu, P. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2001316
Guan, W., Ni, Z., & Hu, Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2002032. https://doi.org/10.1056/NEJMoa2002032
de-Wit, E., van-Doremalen, N., Falzarano, D., & Munster, V. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 2016; 14:523-534. https://doi.org/10.1038/nrmicro.2016.81
Ministerio de Salud Argentino [Internet]. Argentina: Ministerio de Salud; 2020 [acceso 09 de junio de 2020]. Nuevo coronavirus COVID-19, Informes diarios. Disponible en: https://www.argentina.gob.ar/coronavirus/inf orme-diario.
La Nación [Internet]. Argentina: Rodríguez Niell, P.; 2020. [actualizado 28 de mayo de 2020]. Protestas anticuarentena: la provincia de Buenos Aires y la Ciudad dicen que solo actuarán si lo ordenan los jueces. Disponible en: https://www.lanacion.com.ar/politica/manifes taciones-anticuarentena-provincia-buenosaires-ciudad-dicen-nid2370648.
Telesur [Internet]. Argentina: teleSUR - SH; 2020 [actualizado 19 de abril de 2020]. Argentina relaja cuarentena y exceptúa nuevas actividades- Disponible https://www.telesurtv.net/news/argentinarelaja-cuarentena-permitira-actividadescomercia les-20200419-0009.html en:
Lewnard, J. A., & Lo, N. C. Scientific and ethical basis for social-distancing interventions against COVID-19. Lancet Infect. Dis. 2020. https://doi.org/10.1016/S1473-3099(20)30190-0
Feng, S., Shen, C., Xia, N., Song, W., Fan, M., Cowling, B. Rational use of face masks in the COVID-19 pandemic. Lancet. 2020. https://doi.org/10.1016/S2213-2600(20)30134-X
Leung, N., Chu, D., Shiu, E., et al. Respiratory virus shedding in exhaled breath and efficacy of face masks. Nat. Med. 2020. https://doi.org/10.21203/rs.3.rs-16836/v1
